Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome

– Phase 3 ASSERT study on track to report topline data by the end of year – Albireo launches Expanded Access Program (EAP) for Alagille syndrome patients BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare l